Mineralys Therapeutics, Inc. (MLYS)
$25.60-$0.41 (-1.58%) Today
Jon Congleton - OfficerMineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 16 | 255,856 | $6.66M |
| Grant or award | 2 | 237,400 | |
| Option exercise | 30 | 314,918 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
63 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Malcom Rodman - Officer | Option exercise | Common Stock | 5,017 | $0.54 | $3K | |
| David Malcom Rodman - Officer | Option exercise | Common Stock | 5,352 | $1.08 | $6K | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 5,017 | $0.00 | - | |
| David Malcom Rodman - Officer | Option exercise | Stock Option | 5,352 | $0.00 | - | |
 Adam Scott Levy - Officer | Open-market sale | Common Stock | 10,757 | $13.57 | $146K | |
| Jon Congleton - Officer | Open-market sale | Common Stock | 15,271 | $13.52 | $206K |
This is as far as the anonymous view goes. Create a free account for all 63 MLYS filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Warren Eric | Officer | 7,437 | $193K | View on EDGAR | |
| Rodman David Malcom | Officer | 417 | $11K | View on EDGAR | |
| Rodman David Malcom | Officer | 14,056 | $372K | View on EDGAR |
Mineralys Therapeutics, Inc. (MLYS) had 13 insider filings in the last 90 days, with the most recent on 2026-08-25. The full record for MLYS runs to 63 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MLYS were filed in the last 90 days. 4 purchases are on record for this company.
16 insider sales of MLYS were filed in the last 90 days, totaling $6.66M.
This page tracks MLYS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MLYS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
